Open Access

Can evidence from VTE treatment trials with NOACs inform the cardiologist?

Topic: Atrial fibrillation (AF)
Sponsored by Bristol-Myers Squibb and Pfizer Alliance

Congress Session

About the speaker

Doctor Alexander Thomas Cohen

Guy's and St Thomas' NHS Trust Hospitals, London (United Kingdom of Great Britain & Northern Ireland)
12 presentations
0 follower

5 more presentations in this session

Improving patient care with NOACs – Where are we now?

Speaker: Doctor F. Andreotti (Rome, IT)

Thumbnail

Thrombosis versus bleeding risk in NVAF patients – From trials to clinical practice.

Speaker: Professor G. Lip (Liverpool, GB)

Thumbnail

Oral anticoagulation – Managing challenging patients with NVAF.

Speaker: Professor H. Darius (Berlin, DE)

Thumbnail

Are there more NVAF patients that would benefit from anticoagulation with a NOAC?

Speaker: Doctor J. Healey (Hamilton, CA)

Thumbnail

Optimising patient care with NOACs – Panel discussion.

Speaker: Professor H. Darius (Berlin, DE) Doctor F. Andreotti (Rome, IT)

Thumbnail

Access the full session

Oral anticoagulation, thrombosis and bleeding – Improving patient care with NOACs

Speakers: Doctor A. Cohen, Doctor F. Andreotti, Professor G. Lip, Professor H. Darius, Doctor J. Healey...
Thumbnail

About the event

Image

ESC CONGRESS 2016

27 August - 31 August 2016

Sessions Presentations

Related content

Open Access

Prediction of undiagnosed atrial fibrillation (AF) using a machine learning algorithm: PULsE-AI.

29 August 2021

Open Access

Welcome and introductions.

29 August 2021

ESC Premium Access

The collateral damage of COVID-19 on CVD – discussion.

27 August 2021

This platform is supported by

logo Novo Nordisk